Sinil Pharmaceutical Co. Ltd (012790) — Cash Flow Reinvestment Rate
Sinil Pharmaceutical Co. Ltd (012790) has a Cash Flow Reinvestment Rate of 0.16x as of September 2025, reinvesting ₩426.30 Million (capex ₩213.15 Million plus investments ₩-213.15 Million) from operating cash flow of ₩2.62 Billion. Check Sinil Pharmaceutical Co. Ltd (012790) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Sinil Pharmaceutical Co. Ltd Cash Flow Reinvestment Rate (2014–2024)
Historical reinvestment intensity for Sinil Pharmaceutical Co. Ltd across 11 annual periods. Explore 012790 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Sinil Pharmaceutical Co. Ltd (2014–2024)
Year-by-year capital reinvestment analysis for Sinil Pharmaceutical Co. Ltd. For live market cap and broader valuation context, see 012790 market cap overview.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.41x | ₩31.94 Billion | ₩22.69 Billion | ₩8.47 Billion | ▼ -12.0% |
| 2023 | 1.60x | ₩24.24 Billion | ₩15.15 Billion | ₩12.92 Billion | ▼ -9.6% |
| 2022 | 1.77x | ₩24.21 Billion | ₩13.69 Billion | ₩9.33 Billion | ▲ +193.3% |
| 2021 | 0.60x | ₩6.73 Billion | ₩11.16 Billion | ₩3.63 Billion | ▼ -25.7% |
| 2020 | 0.81x | ₩8.98 Billion | ₩11.06 Billion | ₩8.80 Billion | ▲ +1.1% |
| 2019 | 0.80x | ₩9.88 Billion | ₩12.31 Billion | ₩9.73 Billion | ▼ -19.3% |
| 2018 | 1.00x | ₩9.15 Billion | ₩9.19 Billion | ₩8.33 Billion | ▼ -30.2% |
| 2017 | 1.42x | ₩12.36 Billion | ₩8.67 Billion | ₩9.38 Billion | ▲ +315.4% |
| 2016 | 0.34x | ₩4.15 Billion | ₩12.09 Billion | ₩2.57 Billion | ▼ -48.2% |
| 2015 | 0.66x | ₩6.34 Billion | ₩9.56 Billion | ₩5.80 Billion | ▼ -19.7% |
| 2014 | 0.83x | ₩7.70 Billion | ₩9.33 Billion | ₩2.24 Billion | — |